Results 21 to 30 of about 12,522 (211)
The in vitro Activity of Echinocandins Against Clinical Trichophyton rubrum Isolates and Review of the Susceptibility of T. rubrum to Echinocandins Worldwide [PDF]
, 2023 Huilin Su,1– 3,* Weiwei Jiang,4,* Paul E Verweij,3,5 Li Li,2 Junhao Zhu,2 Jiande Han,1 Min Zhu,2 Shuwen Deng6 1Department of Dermatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China; 2Department ...
Zhu M +7 more
core
Pharmaceutics, 2021 Treatment of invasive infections caused by Candida auris is challenging due to the limited therapeutic options. The combination of antifungal drugs may be an interesting and feasible approach to be investigated.
Unai Caballero +3 more
doaj +1 more source
Antibiotics, 2021 Candida glabrata is one of the most prevalent causative pathogens of invasive candidiasis, and multidrug-resistant strains are emerging. We identified two clinical isolates of C. glabrata, BMU10720 and BMU10722 sequentially isolated from one patient with
Qiqi Wang +9 more
doaj +1 more source
Echinocandins for candidemia: a rational choice [PDF]
, 2013 Among antifungal drugs, echinocandins (micafungin, caspofungin and anidulafungin) represent a rational choice for the first-line therapy of candidemia/invasive candidiasis in critically ill patients.
Menichetti, Francesco +1 more
core +2 more sources
Micafungin: A New Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
P H, Chandrasekar, J D, Sobel
openaire +2 more sources
Echinocandins Localized to the Target-Harboring Cell Surface Are Not Degraded but Those Entering the Vacuole Are [PDF]
, 2022 Echinocandin antifungal drugs have a broad spectrum of activities and excellent safety profiles. These agents noncompetitively inhibit the formation of the major polysaccharide component of the fungal cell wall, a reaction catalyzed by the membrane-bound
Micha Fridman +7 more
core +1 more source
Resistance to Echinocandins Complicates a Case of Candida albicans Bloodstream Infection: A Case Report [PDF]
, 2021 Invasive candidiasis is known to be one of the most common healthcare-associated complications and is caused by several Candida species. First-line drugs, particularly echinocandins, are effective, but there are increasing reports of resistance to these ...
Dafne Bongiorno +8 more
core +1 more source
Stimulation of chitin synthesis rescues Candida albicans from echinocandins.
PLoS Pathogens, 2008 Echinocandins are a new generation of novel antifungal agent that inhibit cell wall beta(1,3)-glucan synthesis and are normally cidal for the human pathogen Candida albicans. Treatment of C.
Louise A Walker +5 more
doaj +1 more source
Pharmaceutics, 2023 Candida auris is a multidrug-resistant pathogen against which echinocandins are the drug of choice. However, information on how the chitin synthase inhibitor nikkomycin Z influences the killing activities of echinocandins against C.
Awid Adnan +9 more
doaj +1 more source
Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside. [PDF]
, 2019 Echinocandins (caspofungin, micafungin, anidulafungin), targeting β-1,3-glucan synthesis of the cell wall, represent one of the three currently available antifungal drug classes for the treatment of invasive fungal infections.
Glampedakis, E., Aruanno, M., Lamoth, F.
core +1 more source